Cargando…
SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients
PURPOSE: Patients with X-linked agammaglobulinemia (XLA) are characterized by humoral impairment and are routinely treated with intravenous immunoglobulin (IVIG). In this study, we aimed to investigate the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in IVIG pr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090293/ https://www.ncbi.nlm.nih.gov/pubmed/37063907 http://dx.doi.org/10.3389/fimmu.2023.1156823 |
_version_ | 1785022930336350208 |
---|---|
author | Raphael, Allon Shamriz, Oded Tvito, Ariella Magen, Sophie Goldberg, Shmuel Megged, Orli Lev, Atar Simon, Amos J. Tal, Yuval Somech, Raz Eisenberg, Rachel Toker, Ori |
author_facet | Raphael, Allon Shamriz, Oded Tvito, Ariella Magen, Sophie Goldberg, Shmuel Megged, Orli Lev, Atar Simon, Amos J. Tal, Yuval Somech, Raz Eisenberg, Rachel Toker, Ori |
author_sort | Raphael, Allon |
collection | PubMed |
description | PURPOSE: Patients with X-linked agammaglobulinemia (XLA) are characterized by humoral impairment and are routinely treated with intravenous immunoglobulin (IVIG). In this study, we aimed to investigate the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in IVIG preparations harvested globally and evaluate the transfer of SARS-CoV-2 antibodies to the XLA patient. METHODS: A single-center, prospective cohort study was conducted in the period of November 2020 to November 2022. Clinical and laboratory data, specifically, SARS-CoV-2 spike IgG levels from the serum of 115 IVIG preparations given to 5 XLA patient were collected. Concurrently, SARS-CoV-2 spike IgG levels from the serum of the 5 XLA was collected monthly. RESULTS: Five XLA patients were evaluated within the study period. All were treated monthly with commercial IVIG preparations. A total of 115 IVIG treatments were given over the study period. The origin country and the date of IVIG harvesting was obtained for 111 (96%) of the treatments. Fifty-four IVIG preparations (49%) were harvested during the COVID-19 pandemic of which 76% were positive (>50AU/mL) for SARS-CoV-2 spike antibodies which were subsequently transmitted to the XLA patients in an approximate 10-fold reduction. SARS-CoV2 spike IgG was first detected in IVIG batches that completed their harvest date by September 2021. Positive products were harvested from origin countries with a documented prevalence over 2,000 per 100,000 population. CONCLUSION: As the prevalence of COVID-19 infections rises, detection of SARS-CoV-2 spike IgG in commercial IVIG products increases and is then transmitted to the patient. Future studies are needed to investigate the neutralizing capabilities of SARS-CoV-2 IgG and whether titer levels in IVIG remain consistent as the incidence of infection and vaccination rates in the population changes. |
format | Online Article Text |
id | pubmed-10090293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100902932023-04-13 SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients Raphael, Allon Shamriz, Oded Tvito, Ariella Magen, Sophie Goldberg, Shmuel Megged, Orli Lev, Atar Simon, Amos J. Tal, Yuval Somech, Raz Eisenberg, Rachel Toker, Ori Front Immunol Immunology PURPOSE: Patients with X-linked agammaglobulinemia (XLA) are characterized by humoral impairment and are routinely treated with intravenous immunoglobulin (IVIG). In this study, we aimed to investigate the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in IVIG preparations harvested globally and evaluate the transfer of SARS-CoV-2 antibodies to the XLA patient. METHODS: A single-center, prospective cohort study was conducted in the period of November 2020 to November 2022. Clinical and laboratory data, specifically, SARS-CoV-2 spike IgG levels from the serum of 115 IVIG preparations given to 5 XLA patient were collected. Concurrently, SARS-CoV-2 spike IgG levels from the serum of the 5 XLA was collected monthly. RESULTS: Five XLA patients were evaluated within the study period. All were treated monthly with commercial IVIG preparations. A total of 115 IVIG treatments were given over the study period. The origin country and the date of IVIG harvesting was obtained for 111 (96%) of the treatments. Fifty-four IVIG preparations (49%) were harvested during the COVID-19 pandemic of which 76% were positive (>50AU/mL) for SARS-CoV-2 spike antibodies which were subsequently transmitted to the XLA patients in an approximate 10-fold reduction. SARS-CoV2 spike IgG was first detected in IVIG batches that completed their harvest date by September 2021. Positive products were harvested from origin countries with a documented prevalence over 2,000 per 100,000 population. CONCLUSION: As the prevalence of COVID-19 infections rises, detection of SARS-CoV-2 spike IgG in commercial IVIG products increases and is then transmitted to the patient. Future studies are needed to investigate the neutralizing capabilities of SARS-CoV-2 IgG and whether titer levels in IVIG remain consistent as the incidence of infection and vaccination rates in the population changes. Frontiers Media S.A. 2023-03-29 /pmc/articles/PMC10090293/ /pubmed/37063907 http://dx.doi.org/10.3389/fimmu.2023.1156823 Text en Copyright © 2023 Raphael, Shamriz, Tvito, Magen, Goldberg, Megged, Lev, Simon, Tal, Somech, Eisenberg and Toker https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Raphael, Allon Shamriz, Oded Tvito, Ariella Magen, Sophie Goldberg, Shmuel Megged, Orli Lev, Atar Simon, Amos J. Tal, Yuval Somech, Raz Eisenberg, Rachel Toker, Ori SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients |
title | SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients |
title_full | SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients |
title_fullStr | SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients |
title_full_unstemmed | SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients |
title_short | SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients |
title_sort | sars-cov-2 spike antibody concentration in gamma globulin products from high-prevalence covid-19 countries are transmitted to x-linked agammaglobulinemia patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090293/ https://www.ncbi.nlm.nih.gov/pubmed/37063907 http://dx.doi.org/10.3389/fimmu.2023.1156823 |
work_keys_str_mv | AT raphaelallon sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT shamrizoded sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT tvitoariella sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT magensophie sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT goldbergshmuel sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT meggedorli sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT levatar sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT simonamosj sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT talyuval sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT somechraz sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT eisenbergrachel sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients AT tokerori sarscov2spikeantibodyconcentrationingammaglobulinproductsfromhighprevalencecovid19countriesaretransmittedtoxlinkedagammaglobulinemiapatients |